Insider Selling: LifeMD, Inc. (NASDAQ:LFMD) Insider Sells $1,052,300.00 in Stock

LifeMD, Inc. (NASDAQ:LFMD - Get Free Report) insider Stefan Galluppi sold 85,000 shares of the stock in a transaction on Friday, June 13th. The stock was sold at an average price of $12.38, for a total value of $1,052,300.00. Following the completion of the transaction, the insider now owns 80,449 shares in the company, valued at approximately $995,958.62. This represents a 51.38% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

LifeMD Price Performance

Shares of LFMD stock traded up $0.11 on Tuesday, hitting $13.58. The stock had a trading volume of 1,605,041 shares, compared to its average volume of 1,037,042. The business has a 50 day moving average of $9.02 and a 200 day moving average of $6.79. LifeMD, Inc. has a 12-month low of $3.99 and a 12-month high of $14.20. The stock has a market cap of $617.18 million, a price-to-earnings ratio of -21.22 and a beta of 2.42.

LifeMD (NASDAQ:LFMD - Get Free Report) last posted its earnings results on Tuesday, May 6th. The company reported $0.01 EPS for the quarter, topping the consensus estimate of ($0.04) by $0.05. The firm had revenue of $65.70 million for the quarter, compared to the consensus estimate of $62.47 million. As a group, research analysts expect that LifeMD, Inc. will post -0.56 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. GAMMA Investing LLC bought a new stake in shares of LifeMD during the 1st quarter worth $35,000. CWM LLC increased its stake in shares of LifeMD by 17.5% during the 1st quarter. CWM LLC now owns 9,050 shares of the company's stock worth $49,000 after purchasing an additional 1,351 shares during the last quarter. ProShare Advisors LLC bought a new stake in shares of LifeMD in the 4th quarter worth approximately $51,000. Oxford Asset Management LLP bought a new stake in shares of LifeMD in the 4th quarter worth approximately $52,000. Finally, Balyasny Asset Management L.P. purchased a new position in LifeMD in the fourth quarter valued at approximately $52,000. Institutional investors own 35.52% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the stock. B. Riley raised shares of LifeMD to a "strong-buy" rating in a research note on Tuesday, March 11th. HC Wainwright restated a "buy" rating and issued a $14.00 target price on shares of LifeMD in a report on Wednesday, April 30th. Finally, Cantor Fitzgerald reiterated an "overweight" rating and set a $15.00 price target on shares of LifeMD in a research note on Tuesday, March 11th. One investment analyst has rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, LifeMD currently has a consensus rating of "Buy" and a consensus price target of $11.00.

LifeMD Company Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.